efgartigimod alfa and hyaluronidase (human recombinant)
efgartigimod alfa and hyaluronidase (human recombinant) is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including VYVGART Hytrulo. Available dosage form: injection, solution.
Drug details
- Generic Name
- efgartigimod alfa and hyaluronidase (human recombinant)
- Brand Names
- VYVGART Hytrulo
- Application Number
- BLA761304
- Sponsor
- Argenx US
- NDC Codes
- 4
- Dosage Forms
- INJECTION, SOLUTION
- Routes
- SUBCUTANEOUS
- Active Ingredients
- EFGARTIGIMOD ALFA, HYALURONIDASE (HUMAN RECOMBINANT)
Indications and Usage
1 INDICATIONS AND USAGE VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) ( 1 ) chronic inflammatory demyelinating polyneuropathy (CIDP) ( 1 )